DE60100625D1 - Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina - Google Patents

Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina

Info

Publication number
DE60100625D1
DE60100625D1 DE60100625T DE60100625T DE60100625D1 DE 60100625 D1 DE60100625 D1 DE 60100625D1 DE 60100625 T DE60100625 T DE 60100625T DE 60100625 T DE60100625 T DE 60100625T DE 60100625 D1 DE60100625 D1 DE 60100625D1
Authority
DE
Germany
Prior art keywords
compounds
treating diseases
external retina
ht1a activity
ht1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60100625T
Other languages
English (en)
Other versions
DE60100625T2 (de
Inventor
J Collier
A Kapin
R Hellberg
R Dean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of DE60100625D1 publication Critical patent/DE60100625D1/de
Application granted granted Critical
Publication of DE60100625T2 publication Critical patent/DE60100625T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
DE60100625T 2000-03-17 2001-02-23 Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina Expired - Lifetime DE60100625T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
US190279P 2000-03-17
PCT/US2001/005700 WO2001070222A2 (en) 2000-03-17 2001-02-23 Compounds with 5-ht1a activity useful for treating disorders of the outer retina

Publications (2)

Publication Number Publication Date
DE60100625D1 true DE60100625D1 (de) 2003-09-25
DE60100625T2 DE60100625T2 (de) 2004-02-26

Family

ID=22700682

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60100625T Expired - Lifetime DE60100625T2 (de) 2000-03-17 2001-02-23 Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina

Country Status (19)

Country Link
EP (3) EP1263434A1 (de)
JP (5) JP2003527423A (de)
KR (3) KR20030016239A (de)
CN (2) CN1418100A (de)
AR (1) AR028258A1 (de)
AT (1) ATE247507T1 (de)
AU (5) AU2001238552A1 (de)
BR (3) BR0109193A (de)
CA (3) CA2400637A1 (de)
DE (1) DE60100625T2 (de)
DK (1) DK1263504T3 (de)
ES (1) ES2204848T3 (de)
HK (1) HK1051504A1 (de)
MX (3) MXPA02009071A (de)
PL (1) PL203709B1 (de)
PT (1) PT1263504E (de)
TW (1) TWI268777B (de)
WO (3) WO2001070223A1 (de)
ZA (1) ZA200206350B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
AU2001238552A1 (en) * 2000-03-17 2001-10-03 Alcon, Inc. Compounds with 5-HT2 and 5-HT1A agonist activity for treating glaucoma
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2003300915B2 (en) 2002-12-13 2008-08-28 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
EP1617838A4 (de) * 2003-04-25 2011-07-06 Mitsubishi Tanabe Pharma Corp Zusammensetzung für die orale verabreichung mit alkylendioxybenzol-derivaten
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP2248524A3 (de) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Mittel zur prävention/behandlung von stressbedingter harninkontinenz und vorsorgeuntersuchungsverfahren dafür
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
US8158617B2 (en) 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2896624B1 (de) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclische Verbindungen als Serotonerge und/oder Dopaminerge Mittel und Anwendungen davon
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
PL2498783T3 (pl) 2009-11-09 2019-04-30 Allergan Inc Kompozycje i sposoby stymulowania wzrostu włosów
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
EP2956096A1 (de) 2013-02-15 2015-12-23 Allergan, Inc. Implantat mit langzeit-wirkstofffreisetzung
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
WO2020176599A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
JP2022523774A (ja) 2019-02-27 2022-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物
CN118715014A (zh) * 2021-12-23 2024-09-27 西尔卡雷德夫公司 用于治疗听力疾病的4-苯基-四氢吡啶衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (de) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
AU2001238552A1 (en) * 2000-03-17 2001-10-03 Alcon, Inc. Compounds with 5-HT2 and 5-HT1A agonist activity for treating glaucoma

Also Published As

Publication number Publication date
JP2011037901A (ja) 2011-02-24
WO2001070230A3 (en) 2002-04-25
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
ES2204848T3 (es) 2004-05-01
AU2001239836A1 (en) 2001-10-03
BR0109230A (pt) 2003-06-03
MXPA02009071A (es) 2003-05-23
AU2005202600B2 (en) 2008-07-31
JP2011153158A (ja) 2011-08-11
EP1263434A1 (de) 2002-12-11
MXPA02009072A (es) 2003-03-12
CA2400639A1 (en) 2001-09-27
JP4789231B2 (ja) 2011-10-12
ATE247507T1 (de) 2003-09-15
EP1263504B1 (de) 2003-08-20
KR100749191B1 (ko) 2007-08-13
CA2399985A1 (en) 2001-09-27
PT1263504E (pt) 2003-12-31
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
TWI268777B (en) 2006-12-21
KR20030009390A (ko) 2003-01-29
KR20020082885A (ko) 2002-10-31
AR028258A1 (es) 2003-04-30
CN1418121A (zh) 2003-05-14
EP1263504A2 (de) 2002-12-11
WO2001070222A2 (en) 2001-09-27
CN1198605C (zh) 2005-04-27
JP2003527422A (ja) 2003-09-16
WO2001070222A3 (en) 2002-07-25
JP2003527423A (ja) 2003-09-16
DK1263504T3 (da) 2003-12-08
WO2001070230A2 (en) 2001-09-27
WO2001070223A1 (en) 2001-09-27
KR20030016239A (ko) 2003-02-26
JP2003527427A (ja) 2003-09-16
ZA200206350B (en) 2003-08-08
MXPA02009073A (es) 2003-03-12
PL358306A1 (en) 2004-08-09
PL203709B1 (pl) 2009-11-30
CA2400639C (en) 2011-08-16
BR0109193A (pt) 2003-05-27
EP1267878A2 (de) 2003-01-02
AU4531001A (en) 2001-10-03
DE60100625T2 (de) 2004-02-26
CN1418100A (zh) 2003-05-14
CA2400637A1 (en) 2001-09-27
HK1051504A1 (en) 2003-08-08

Similar Documents

Publication Publication Date Title
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60230425D1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE69919580D1 (de) Verbindungen zur anwendung bei der behandlung entzündlicher erkrankungen
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE60022826D1 (de) Absorbierender Wegwerfartikel zur Behandlung von Fäkalien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition